One-in-a-million people are living with EHE worldwide.

Our mission is to find treatments and a cure for this rare cancer by advancing research and driving collaboration between patients, researchers, and clinicians.

We envision a world where Epithelioid Hemangioendothelioma (EHE) is easily diagnosed and treatable. Join our dedicated community by subscribing to our emails.

EHE Biobank

Patients Powering Research for EHE

Patients are the key to finding new treatments for EHE! Researchers need tumor tissue and fluid from EHE patients to understand disease progression and speed the development of new drugs and therapies.

EHE Global Patient Registry

Patients Powering Research for EHE

The EHE Global Patient Registry empowers people with Epithelioid Hemangioendothelioma (EHE) to join together to improve our understanding of this ultra-rare sarcoma. We need every EHE patient to join this critical tool used to support researchers searching for treatments and a cure for EHE.

Consensus Paper on EHE Management

The Consensus Paper is a powerful, EHE-specific resource for patients, caregivers, and medical professionals that answers critical questions regarding diagnosis and treatment. Patients are encouraged to read it to better understand EHE and facilitate more informed discussions and decision-making with medical teams.

Latest EHE News, Events and Research

test tubes

GDF-15 Predicts Epithelioid Hemangioendothelioma Aggressiveness and is Down-regulated by Sirolimus Through ATF4/ATF5 Suppression

By The EHE Foundation | September 27, 2024

Drs. Silvia Stacchiotti, Sandro Pasquali, and Nadia Zaffaroni (IRCCS – INT, Milan, Italy) and colleagues published their promising findings in Clinical Cancer Research, September 16, 2024. This study, funded in part by The EHE Foundation in partnership with EHE Rare Cancer Charity (UK), aimed to assess the efficacy of sirolimus for the treatment of EHE […]

Read More
Ajay Pobbati, PhD and Brian Rubin, MD, PhD at the Cleveland Clinic

Harnessing Cyclin-dependent Kinase Inhibitors to Gain Mechanistic Insight Into the Regulation of the TAZ-CAMTA1 Fusion Protein

By The EHE Foundation | September 23, 2024

Ajay Pobbati, PhD, Brian Rubin, MD, PhD, and colleagues at the Cleveland Clinic published their findings from the study “CDK9 inhibition by dinaciclib is a therapeutic vulnerability in epithelioid hemangioendothelioma” in Clinical Cancer Research, September 13, 2024. This study, funded in part by a grant from The EHE Foundation, provides a strong rationale for investigating […]

Read More
Community Connections for Caregivers: Anticipatory Grief

EHE Community Connections for Caregivers: Anticipatory Grief

By The EHE Foundation | September 9, 2024

As a caregiver, it can be hard to not think about the future and what it may or may not hold. In doing so, it is common for caregivers to experience anticipatory grief, in which we mourn the loss of our loved one while they are still here as well as grieve the future that […]

Read More
Denise Robinson, EHE Foundation Executive Director

The EHE Foundation Appoints New Executive Director

By The EHE Foundation | August 14, 2024

On behalf of the Board of Directors of The EHE Foundation, Jenni Kovach, Board President has announced the appointment of Denise Robinson as the new Executive Director for the Foundation.  Like many people, Denise had not heard of EHE until her friend was diagnosed in 2017 with an aggressive form of the disease. She soon […]

Read More
The Pledge: Edition 37, Q2 - April-June, 2024

The Pledge: Edition 37, Q2 – April-June, 2024

By The EHE Foundation | August 8, 2024

Publication of The Pledge quarterly newsletter is led by the EHE Rare Cancer Charity (UK). EHE patient advocacy groups from around the globe. provide content including research news, patient and fundraising stories, and much more. Click here to view the most recent edition of our online EHE newsletter, The Pledge.

Read More
The EHE Foundation Attends ASCO 2024

Advancing our Mission, Representing EHE Patients at ASCO 2024

By The EHE Foundation | June 19, 2024

Our Interim Executive Director and Director of Research, Denise Robinson, recently represented epithelioid hemangioendothelioma (EHE) patients at the 2024 ASCO Annual Meeting in Chicago, Illinois, where nearly 40,000 global oncology professionals convened. The American Society of Clinical Oncology (ASCO), is the world’s leading organization for oncology, bringing together advocates, healthcare providers, and related professionals to […]

Read More
2024 EHE Fun Run & Walk Recap

Reflecting on Success: 2024 EHE Fun Run & Walk Recap

By The EHE Foundation | June 18, 2024

With enthusiasm and gratitude, The EHE Foundation is proud to celebrate another successful year of the Annual EHE Fun Run & Walk. This event, dedicated to supporting The EHE Foundation’s mission to find treatments and a cure for epithelioid hemangioendothelioma (EHE), always brings our community together in an extraordinary way! With 1387 registrations, our hearts […]

Read More
EHE community donations expand grant.

Planting Seeds for Future Developments: EHEF Research Grant Grows

By The EHE Foundation | June 14, 2024

The EHE Foundation invests in novel EHE research yearly through its EHE Research Grants Program. The program officially began in 2021, with only a few applicants interested in EHE research. Today, 10 applicants have submitted proposals in our 2024 grants cycle.  Along the way, we have had the good fortune to meet and collaborate with […]

Read More
Ikena Oncology's IK-930 Trial Discontinued

Ikena Oncology IK-930 Update

By The EHE Foundation | June 7, 2024

On May 28, 2024, Ikena Oncology announced they are discontinuing the development of IK-930. We share your frustration and disappointment and understand the devastating impact felt by patients. Following this announcement, we met with Ikena to impress upon them the urgency and importance that patients deriving benefits from IK-930 continue to have access to the […]

Read More